nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/16828658-ecg-199-3-107-114nogr-1945Research ArticleОБЗОРREVIEWКоморбидность гастроэнтерологической и кардиоваскулярной патологии как проблема клинической практикиComorbidity of gastroenterological and cardiovascular pathology as a problem of clinical practicehttps://orcid.org/0000-0003-1469-0367РябоваА. Ю.RyabovaA. Yu.

Рябова Анна Юрьевна - доктор медицинских наук, доцент, профессор кафедры терапии, гастроэнтерологии и пульмонологии.

410012, Саратов, Большая Казачья ул.,112

Anna Yu. Ryabova - Professor of the Department of Therapy, Gastroenterology and Pulmonology; assistant professor; Doctor of Medical Sciences; Scopus Author ID: 57213286335.

410012, Bolshaya Kazachyia St., 112, Saratov

anna917@bk.ruhttps://orcid.org/0000-0002-5056-4504КозловаИ. В.KozlovaI. V.

Козлова Ирина Вадимовна - доктор медицинских наук, профессор, заведующая кафедрой терапии, гастроэнтерологии и пульмонологии.

410012, Саратов, Большая Казачья ул.,112

Irina V. Kozlova - Doctor of Medical Sciences, Professor, Head of the Department of Therapy, Gastroenterology and Pulmonology; Scopus Author ID: 7102626490.

410012, Bolshaya Kazachyia St., 112, Saratov

https://orcid.org/0000-0001-6186-6746ШаповаловаТ. Г.ShapovalovaT. G.

Шаповалова Татьяна Германовна - доктор медицинских наук, профессор, профессор кафедры терапии, гастроэнтерологии и пульмонологии.

410012, Саратов, Большая Казачья ул.,112

Tatyana G. Shapovalova - Professor of the Department of Therapy, Gastroenterology and Pulmonology; Professor; Doctor of Medical Sciences, Scopus Author ID: 6603614978.

410012, Bolshaya Kazachyia St., 112, Saratov

https://orcid.org/0000-0002-0282-4359ШашинаМ. М.ShashinaM. M.

Шашина Марина Михайловна - кандидат медицинских наук, доцент кафедры терапии, гастроэнтерологии и пульмонологии.

410012, Саратов, Большая Казачья ул.,112

Marina M. Shashina - Associate Professor of the Department of Therapy, Gastroenterology and Pulmonology; assistant professor; Candidate of Medical Sciences.

410012, Bolshaya Kazachyia St., 112, Saratov

ФГБОУ ВО Саратовский государственный медицинский университет им. В.И. Разумовского МЗ РФРоссияSaratov State Medical University n. a. V.I. RazumovskyRussian Federation20220410202203107114Copyright © Рябова А.Ю., Козлова И.В., Шаповалова Т.Г., Шашина М.М., 20222022Рябова А.Ю., Козлова И.В., Шаповалова Т.Г., Шашина М.М.Ryabova A.Y., Kozlova I.V., Shapovalova T.G., Shashina M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1945Цель обзора

Цель обзора: обобщить имеющиеся в литературе и представить практикующему врачу сведения о связи заболеваний желудочно-кишечного тракта с кардиоваскулярной патологией.

Основные положения

Основные положения. Коморбидность заболеваний желудочно-кишечного тракта и кардиоваскулярной патологии (КВП) обусловлена сходными факторами риска и патогенетическими механизмами. Результаты научных исследований пациентов с патологией ЖКТ свидетельствуют о более высоких кардиальных рисках и частоте развития СВП, в сравнении с общей популяцией.

Заключение

Заключение. Заболевания желудочно-кишечного тракта могут выступать в качестве факторов риска, звеньев патогенеза, элементов клинической картины патологии органов пищеварения. Необходим мультидисциплинарный подход в диагностике и лечении пациентов с коморбидными сердечно-сосудистой патологии болезнями ЖКТ для оптимизации тактики ведения.

The purpose of the review: to summarize the information available in the literature and to present to the practitioner information on the relationship of diseases of the gastrointestinal tract with cardiovascular pathology.

Basic provisions

Basic provisions. The comorbidity of diseases of the gastrointestinal tract and cardiovascular pathology (CVP) is due to similar risk factors and pathogenetic mechanisms. The results of scientifi c studies of patients with gastrointestinal tract pathology indicate higher cardiac risks and the incidence of CVP in comparison with the general population.

Conclusion

Conclusion. Gastrointestinal disorders can act as risk factors, links in pathogenesis, elements of the clinical picture of CVP. A multidisciplinary approach is needed in the treatment of patients with chronic gastrointestinal pathology in order to best address the underlying problems and existing cardiovascular diseases in this category.

коморбидностьгастроэнтерологические заболеваниякардиоваскулярная патологияcomorbiditygastroenterological diseasescardiovascular pathologyReferencesОганов Р. Г., Симаненков В. И., Бакулин И. Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5–66. https://doi.org/10.15829/1728–8800– 2019–1–5–66Oganov R. G., Simanenkov V. I., Bakulin I. G., et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5–66. (In Russ.) doi:10.15829/1728–8800–2019–1–5–66Martins J.C.S., Mendes L. S.C., Duraes A. R. Cardiovascular Complications of Gastrointestinal Diseases. J Gastrointest Dig Syst. 2015;5:351. doi:10.4172/2161–069X.1000351Martins J.C.S., Mendes L. S.C., Duraes A. R. Cardiovascular Complications of Gastrointestinal Diseases. J Gastrointest Dig Syst. 2015;5:351. doi:10.4172/2161–069X.1000351Gesualdo M., Scicchitano P., Carbonara S., et al. Th e association between cardiac and gastrointestinal disorders: causal or casual link? J Cardiovasc Med (Hagerstown). 2016 May;17(5):330–8. doi: 10.2459/JCM.0000000000000351. PMID: 26702598.Gesualdo M., Scicchitano P., Carbonara S., et al. Th e association between cardiac and gastrointestinal disorders: causal or casual link? J Cardiovasc Med (Hagerstown). 2016 May;17(5):330–8. doi: 10.2459/JCM.0000000000000351. PMID: 26702598.Симаненков В. И., Маев И. В., Ткачева О. Н. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20 (1): 2758. doi: 10.15829/1728–8800–2021–2758Simanenkov V.I., Maev I. V., Tkacheva O. N., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Th erapy and Prevention. 2021;20(1):2758. (in Russ) doi:10.15829/1728–8800–2021–2758Issac T. T., Dokainish H., Lakkis N. M. Role of infl ammation in initiation and perpetuation of atrial fi brillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50: 2021–2028.Issac T. T., Dokainish H., Lakkis N. M. Role of infl ammation in initiation and perpetuation of atrial fi brillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50: 2021–2028.Mohamed A., Ochoa Crespo D., Kaur G., et al. Gastroesophageal Reflux and Its Association With Atrial Fibrillation: A Traditional Review. Cureus. 2020, September 11;12(9): e10387. doi:10.7759/cureus.10387Mohamed A., Ochoa Crespo D., Kaur G., et al. Gastroesophageal Reflux and Its Association With Atrial Fibrillation: A Traditional Review. Cureus. 2020, September 11;12(9): e10387. doi:10.7759/cureus.10387Maruyama T., Fukata M., Akashi K. Association of atrial fi brillation and gastroesophageal refl ux disease: natural and therapeutic linkage of the two common diseases. J Arrhythm. 2018, 35:43–51. 10.1002/joa3.12125Maruyama T., Fukata M., Akashi K. Association of atrial fi brillation and gastroesophageal refl ux disease: natural and therapeutic linkage of the two common diseases. J Arrhythm. 2018, 35:43–51. 10.1002/joa3.12125Шавкута Г. В., Черкасов М. Ф., Пахомова В. М. и др. Желудок в грудной клетке, или что нам известно о гигантских грыжах пищеводного отверстия диафрагмы. Южно-Российский журнал терапевтической практики. 2021;2(1):115–120. doi:10.21886/2712–8156–2021–2–1–115–120Shavkuta G. V., Cherkasov M. F., Pakhomova V. M., et al. Stomach in the chest or what we know about giant hiatal hernias. South Russian Journal of Th erapeutic Practice. 2021;2(1):115–120. (In Russ.) doi:10.21886/2712–8156–2021–2–1–115–120Xu L., Zhang Y., Xie J., Liu Y., Xu L. Association between gastroesophageal refl ux disease and atrial fi brillation: a systematic review and meta-analysis. Rev Esp Enferm Dig. 2019; 111:874–9. doi:10.17235/reed.2019.5389/2017Xu L., Zhang Y., Xie J., Liu Y., Xu L. Association between gastroesophageal refl ux disease and atrial fi brillation: a systematic review and meta-analysis. Rev Esp Enferm Dig. 2019; 111:874–9. doi:10.17235/reed.2019.5389/2017Jeremic N., Petkovic A., Srejovic I., et al. Eff ects of ischemia and omeprazole preconditioning on functional recovery of isolated rat heart. Rev Bras Cir Cardiovasc. 2015, 30:266–275. doi:10.5935/1678–9741.20150020Jeremic N., Petkovic A., Srejovic I., et al. Eff ects of ischemia and omeprazole preconditioning on functional recovery of isolated rat heart. Rev Bras Cir Cardiovasc. 2015, 30:266–275. doi:10.5935/1678–9741.20150020Ивашкин В. Т., Маев И. В., Шептулин А. А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии. Рос журн гастроэнтерол гепатол колопроктол 2017; 27(1):50– 61. DOI: 10.22416/1382–4376–2017-27-1–50–61Ivashkin V. T., Mayev I. V., Sheptulin A. A., et al. Diagno sis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50–61. (In Russ.) doi:10.22416/1382–4376–2017-27-1–50–61Saeed M., Bhandohal J. S., Visco F., Pekler G., Mushiyev S. Gastrocardiac syndrome: a forgotten entity. Am J Emerg Med. 2018; 36:1525. doi:10.1016/j.ajem.2018.05.002Saeed M., Bhandohal J. S., Visco F., Pekler G., Mushiyev S. Gastrocardiac syndrome: a forgotten entity. Am J Emerg Med. 2018; 36:1525. doi:10.1016/j.ajem.2018.05.002Qureshi K., Naeem N., Saleem S., et al. Recurrent Episodes of Paroxysmal Supraventricular Tachycardia Triggered by Dyspepsia: A Rare Case of Gastrocardiac Syndrome. Cureus. 2021;13(9): e17966. Published 2021 Sep 14. doi:10.7759/cureus.17966Qureshi K., Naeem N., Saleem S., et al. Recurrent Episodes of Paroxysmal Supraventricular Tachycardia Triggered by Dyspepsia: A Rare Case of Gastrocardiac Syndrome. Cureus. 2021;13(9): e17966. Published 2021 Sep 14. doi:10.7759/cureus.17966Chmiela M., Gajewski A., Rudnicka K. Helicobacter pylori vs coronary heart disease – searching for connections. World J Cardiol. 2015;7(4):187-203. doi:10.4330/wjc.v7.i4.187Chmiela M., Gajewski A., Rudnicka K. Helicobacter pylori vs coronary heart disease – searching for connections. World J Cardiol. 2015;7(4):187-203. doi:10.4330/wjc.v7.i4.187Мороз Е. В., Каратеев А. Е., Крюков Е. В., Чернецов В. А. Желудочно-кишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика. Научно-практическая ревматология. 2017;55(6):675–684. doi: 10.14412/1995–4484–2017-675–684Moroz E. V., Karateev A. E., Kryukov E. V., Cher netsov V. A. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment, and prevention. Nauchno-P rakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):675–684. (In Russ.) doi: 10.14412/1995–4484–2017-675–684Симонова Ж. Г., Мартусевич А. К., Тарловская Е. И. Клинико-патогенетические аспекты течения ишемической болезни сердца в сочетании с язвенной болезнью. Терапевтический архив. 2014; 1: 33–36.Simonova Zh.G., Martusevich A. K., Tarlovskaya E. I. Clinical and pathogenetic aspects of the course of coronary heart disease in combination with peptic ulcer. Th erapeutic archive; 2014;(1): 33–36. (in Russ.)Buzás G. M. Metabolic consequences of Helicobacter pylori infection and eradication. World J Gastroenterol. 2014;20(18):5226–5234. doi:10.3748/wjg.v20.i18.5226Buzás G. M. Metabolic consequences of Helicobacter pylori infection and eradication. World J Gastroenterol. 2014;20(18):5226–5234. doi:10.3748/wjg.v20.i18.5226V Lee M., Baek H., Park J. S., et al. Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-s ectional study. PLoS One. 2018;13(3): e0193646. Published 2018 Mar 2. doi:10.1371/journal.pone.0193646V Lee M., Baek H., Park J. S., et al. Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-s ectional study. PLoS One. 2018;13(3): e0193646. Published 2018 Mar 2. doi:10.1371/journal.pone.0193646Kountouras J., Polyzos S. A., Katsinelos P., et al. Cardio- cerebrovascular disease and Helicobacter pylori-r elated metabolic syndrome: We consider eradication therapy as a potential cardio-c erebrovascular prevention strategy. Int J Cardiol. 2017;229: 17-18. doi: 10.1016/j.ijcard.2016.11.265Kountouras J., Polyzos S. A., Katsinelos P., et al. Cardio- cerebrovascular disease and Helicobacter pylori-r elated metabolic syndrome: We consider eradication therapy as a potential cardio-c erebrovascular prevention strategy. Int J Cardiol. 2017;229: 17-18. doi: 10.1016/j.ijcard.2016.11.265Zuin M., Rigatelli G., Del Favero G., et al. Coronary artery disease and Helicobacter pylori infection: Should we consider eradication therapy as cardiovascular prevention strategy? Int J Cardiol. 2016;223: 711–712. doi: 10.1016/j.ijcard.2016.08.320Zuin M., Rigatelli G., Del Favero G., et al. Coronary artery disease and Helicobacter pylori infection: Should we consider eradication therapy as cardiovascular prevention strategy? Int J Cardiol. 2016;223: 711–712. doi: 10.1016/j.ijcard.2016.08.320Fallah, Soudabeh et al. Helicobacter pylori Infection is a Signifi cant Factor Risk for Hyperhomocysteinemia in the Patients with Coronary Artery Disease. Brazilian Archives of Biology and Technology. 2016; 59: e16150509. doi: 10.1590/1678–4324–2016150509Fallah, Soudabeh et al. Helicobacter pylori Infection is a Signifi cant Factor Risk for Hyperhomocysteinemia in the Patients with Coronary Artery Disease. Brazilian Archives of Biology and Technology. 2016; 59: e16150509. doi: 10.1590/1678–4324–2016150509Хлынова О. В., Степина Е. А. Особенности состояния сосудистого эндотелия у лиц с тяжелыми формами воспалительных заболеваний кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(5):98–104. doi:10.22416/1382–4376–2018–28–5–98–104Khlynova O. V., Stepina E. A. Specific Features of Vascular Endothelium in Patients with Severe Forms of Inflammatory Bowel Diseases. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(5):98–104. (In Russ.) doi:10.22416/1382–4376–2018–28–5–98–104Bunu D.M., Timoft e C. E., Ciocoiu M., et al. Cardiovascular Manifestations of Infl ammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies. Gastroenterol Res Pract. 2019 Jan 13;2019:3012509. doi: 10.1155/2019/3012509. PMID: 30733802; PMCID: PMC6348818.Bunu D.M., Timoft e C. E., Ciocoiu M., et al. Cardiovascular Manifestations of Infl ammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies. Gastroenterol Res Pract. 2019 Jan 13;2019:3012509. doi: 10.1155/2019/3012509. PMID: 30733802; PMCID: PMC6348818.Patel R.S., Rohit Reddy S., Llukmani A., et al. Cardiovascular Manifestations in Infl ammatory Bowel Disease: A Systematic Review of the Pathogenesis and Management of Pericarditis. Cureus. 2021 Mar 20;13(3): e14010. doi: 10.7759/cureus.14010. PMID: 33884251; PMCID: PMC8054944.Patel R.S., Rohit Reddy S., Llukmani A., et al. Cardiovascular Manifestations in Infl ammatory Bowel Disease: A Systematic Review of the Pathogenesis and Management of Pericarditis. Cureus. 2021 Mar 20;13(3): e14010. doi: 10.7759/cureus.14010. PMID: 33884251; PMCID: PMC8054944.Olpin J.D., Sjoberg B. P., Stilwill S. E., Jensen L. E., Rezvani M., Shaaban A. M. Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease. Radiographics. 2017 Jul-A ug;37(4):1135–1160. doi: 10.1148/rg.2017160121. Epub 2017 May 26. PMID: 28548906.Olpin J.D., Sjoberg B. P., Stilwill S. E., Jensen L. E., Rezvani M., Shaaban A. M. Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease. Radiographics. 2017 Jul-A ug;37(4):1135–1160. doi: 10.1148/rg.2017160121. Epub 2017 May 26. PMID: 28548906.Castellon X., Bogdanova V. Chronic Inflammatory Diseases and Endothelial Dysfunction. Aging Dis. 2016;7(1):81–89. Published 2016 Jan 2. doi:10.14336/AD.2015.0803Castellon X., Bogdanova V. Chronic Inflammatory Diseases and Endothelial Dysfunction. Aging Dis. 2016;7(1):81–89. Published 2016 Jan 2. doi:10.14336/AD.2015.0803Bracamonte-B aran W., Čiháková D. Cardiac autoimmunity: myocarditis. Advances in Experimental Medicine and Biology. 2017;1003:187-221. doi: 10.1007/978–3–319–57613–8_10Bracamonte-B aran W., Čiháková D. Cardiac autoimmunity: myocarditis. Advances in Experimental Medicine and Biology. 2017;1003:187-221. doi: 10.1007/978–3–319–57613–8_10Efe T. H., Cimen T., Ertem A. G., et al. Atrial electromechanical properties in infl ammatory bowel disease. Echocardiography. 2016;33(9):1309–1316. doi: 10.1111/echo.13261Efe T. H., Cimen T., Ertem A. G., et al. Atrial electromechanical properties in infl ammatory bowel disease. Echocardiography. 2016;33(9):1309–1316. doi: 10.1111/echo.13261Pattanshetty D. J., Gajulapalli R. D., Anna K., Biyyani R. S. S. Prevalence of QT interval prolongation in infl ammatory bowel disease. Th e Turkish Journal of Gastroenterology. 2016;27(2):136–142. doi: 10.5152/tjg.2015.150349Pattanshetty D. J., Gajulapalli R. D., Anna K., Biyyani R. S. S. Prevalence of QT interval prolongation in infl ammatory bowel disease. Th e Turkish Journal of Gastroenterology. 2016;27(2):136–142. doi: 10.5152/tjg.2015.150349Engel T., Ben- Horin S., Beer- Gabel M. Autonomic dysfunction correlates with clinical and infl ammatory activity in patients with Crohn’s disease. Infl ammatory Bowel Diseases. 2015;21(10):2320–2326. doi: 10.1097/MIB.0000000000000508Engel T., Ben- Horin S., Beer-Gabel M. Autonomic dysfunction correlates with clinical and infl ammatory activity in patients with Crohn’s disease. Infl ammatory Bowel Diseases. 2015;21(10):2320–2326. doi: 10.1097/MIB.0000000000000508Koutroumpakis E., Ramos-R ivers C., Regueiro M., et al. Association Between Long- Term Lipid Profi les and Disease Severity in a Large Cohort of Patients with Infl ammatory Bowel Disease. Dig Dis Sci. 2016 Mar;61(3):865–71. doi: 10.1007/s10620–015–3932–1. Epub 2015 Oct 29. PMID: 26514677.Koutroumpakis E., Ramos-R ivers C., Regueiro M., et al. Association Between Long- Term Lipid Profi les and Disease Severity in a Large Cohort of Patients with Infl ammatory Bowel Disease. Dig Dis Sci. 2016 Mar;61(3):865–71. doi: 10.1007/s10620–015–3932–1. Epub 2015 Oct 29. PMID: 26514677.Harbord M., Annese V., Vavricka S. R., et al. Th e fi rst European evidence-b ased consensus on extra-i ntestinal manifestations in infl ammatory bowel disease. Journal of Crohn’s and Colitis. 2016;10(3):239–254. doi: 10.1093/ecco-jcc/jjv213Harbord M., Annese V., Vavricka S. R., et al. Th e fi rst European evidence-b ased consensus on extra-i ntestinal manifestations in infl ammatory bowel disease. Journal of Crohn’s and Colitis. 2016;10(3):239–254. doi: 10.1093/ecco-jcc/jjv213Ойноткинова О. Ш., Никонов Е. Л., Демидова Т. Ю. и др. Изменения кишечной микробиоты как фактор риска развития дислипидемии, атеросклероза и роль пробиотиков в их профилактике. Терапевтический архив. 2020; 92 (9): 94–101. doi: 10.26442/00403660.2020.09.000784Oynotkinova O.S., Nikonov E. L., Demidova T. Y., et al. Changes in the intestinal microbiota as a risk factor for dyslipidemia, atherosclerosis and the role of probiotics in their prevention. Th erapeutic Archive. 2020; 92 (9): 94–101. doi: 10.26442/00403660.2020.09.000784Воспалительные механизмы в генезе атеросклероза / Г. А. Фадеев, Р. Г. Фатыхов, Н. А. Цибулькин, и др. // Вестник современной клинической медицины. – 2020. – Т. 13, вып. 6. – С. 62–67. doi: 10.20969/VSKM.2020.13(6).62–67Fadeev G.A., Fatykhov R. G., Tsibulkin N. A., Mikhoparova O. Yu., Oschepkova O. B., Abdrak hmanova A. I. Inflammatory mechanisms in genesis of atherosclerosis. Th e Bulletin of Contemporary Clinical Medicine. 2020; 13 (6): 62–67. (in Russ.) doi: 10.20969/VSKM.2020.13(6).62–67Mafune A., Iwamoto T., Tsutsumi Y., et al. Associations among serum trimethylamine-N -oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study. Clin Exp Nephrol. 2016 Oct;20(5):731–739. doi: 10.1007/s10157-015–1207-yMafune A., Iwamoto T., Tsutsumi Y., et al. Associations among serum trimethylamine-N -oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study. Clin Exp Nephrol. 2016 Oct;20(5):731–739. doi: 10.1007/s10157-015–1207-yOwczarek D., Cibor D., Głowacki M. K., Rodacki T., Mach T. Infl ammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability. World J Gastroenterol. 2014;20(1):53–63. doi:10.3748/wjg.v20.i1.53Owczarek D., Cibor D., Głowacki M. K., Rodacki T., Mach T. Infl ammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability. World J Gastroenterol. 2014;20(1):53–63. doi:10.3748/wjg.v20.i1.53Landman C., Nahon S., Cosnes J., et al. Portomesenteric vein thrombosis in patients with infl ammatory bowel disease. Inflamm Bowel Dis. 2013;19(3):582–589. doi:10.1097/MIB.0b013e31827eea5fLandman C., Nahon S., Cosnes J., et al. Portomesenteric vein thrombosis in patients with infl ammatory bowel disease. Inflamm Bowel Dis. 2013;19(3):582–589. doi:10.1097/MIB.0b013e31827eea5fDaub S., Lutgens E., Münzel T., Daiber A. CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease-Th e Pros and Cons for Cardioprotection. Int J Mol Sci. 2020;21(22):8533. Published 2020 Nov 12. doi:10.3390/ijms21228533Daub S., Lutgens E., Münzel T., Daiber A. CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease-Th e Pros and Cons for Cardioprotection. Int J Mol Sci. 2020;21(22):8533. Published 2020 Nov 12. doi:10.3390/ijms21228533Ganguly P., Alam S. F. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6. doi:10.1186/1475–2891–14–6Ganguly P., Alam S. F. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6. doi:10.1186/1475–2891–14–6Aarestrup J., Jess T., Kobylecki C. J., Nordestgaard B. G., Allin K. H. Cardiovascular Risk Profi le Among Patients With Infl ammatory Bowel Disease: A Population-b ased Study of More Th an 100 000 Individuals. J Crohns Colitis. 2019 Mar 26;13(3):319–323. doi: 10.1093/ecco-jcc/jjy164Aarestrup J., Jess T., Kobylecki C. J., Nordestgaard B. G., Allin K. H. Cardiovascular Risk Profi le Among Patients With Infl ammatory Bowel Disease: A Population-b ased Study of More Th an 100 000 Individuals. J Crohns Colitis. 2019 Mar 26;13(3):319–323. doi: 10.1093/ecco-jcc/jjy164Chavez L., Mayrovitz H. N. Assessing the Impact of Helicobacter pylori Infection and Infl ammatory Bowel Disease on Pulse Wave Velocity and Arterial Stiff ness. Cureus. 2021;13(5): e14944. doi:10.7759/cureus.14944Chavez L., Mayrovitz H. N. Assessing the Impact of Helicobacter pylori Infection and Infl ammatory Bowel Disease on Pulse Wave Velocity and Arterial Stiff ness. Cureus. 2021;13(5): e14944. doi:10.7759/cureus.14944Фомина Е. С., Никифоров В. С. Артериальная жесткость и сосудистое старение: последствия артериальной гипертензии. Архивъ внутренней медицины. 2021; 11(3): 196–202. doi:10.20514/2226–6704–2021–11–3–196–202Fomina E. S., Nikiforov V. S. Arterial Stiffness and Vascular Aging: Eff ects of Hypertension. Th e Russian Archives of Internal Medicine. 2021;11(3):196–202. (in Russ.) doi:10.20514/2226–6704–2021–11–3–196–202Cappello M., Licata A., Calvaruso V., et al. Increased expression of markers of early atherosclerosis in patients with infl ammatory bowel disease. Eur J Intern Med. 2017 Jan;37:83–89. doi: 10.1016/j.ejim.2016.10.004Cappello M., Licata A., Calvaruso V., et al. Increased expression of markers of early atherosclerosis in patients with infl ammatory bowel disease. Eur J Intern Med. 2017 Jan;37:83–89. doi: 10.1016/j.ejim.2016.10.004Biondi R.B., Salmazo P. S., Bazan S. G.Z., Hueb J. C., de Paiva S. A.R., Sassaki L. Y. Cardiovascular Risk in Individuals with Infl ammatory Bowel Disease. Clin Exp Gastroenterol. 2020;13:107-113. Published 2020 Apr 24. doi:10.2147/CEG.S243478Biondi R.B., Salmazo P. S., Bazan S. G.Z., Hueb J. C., de Paiva S. A.R., Sassaki L. Y. Cardiovascular Risk in Individuals with Infl ammatory Bowel Disease. Clin Exp Gastroenterol. 2020;13:107-113. Published 2020 Apr 24. doi:10.2147/CEG.S243478Patel V. B., Why H. J., Richardson P. J., Preedy V. R. Th e eff ects of alcohol on the heart. Adverse Drug React Toxicol Rev. 1997 Mar;16(1):15–43.Patel V. B., Why H. J., Richardson P. J., Preedy V. R. Th e eff ects of alcohol on the heart. Adverse Drug React Toxicol Rev. 1997 Mar;16(1):15–43.Chayanupatkul M., Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014;8(3):308–315. doi:10.1007/s12072–014–9531-yChayanupatkul M., Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014;8(3):308–315. doi:10.1007/s12072–014–9531-yCarvalho M. V.H., Kroll P. C., Kroll R. T.M., Carvalho V. N. Cirrhotic cardiomyopathy: the liver affects the heart. Braz J Med Biol Res. 2019;52(2): e7809. doi:10.1590/1414–431X20187809Carvalho M. V.H., Kroll P. C., Kroll R. T.M., Carvalho V. N. Cirrhotic cardiomyopathy: the liver affects the heart. Braz J Med Biol Res. 2019;52(2): e7809. doi:10.1590/1414–431X20187809Ruiz-del-Á rbol L., Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol. 2015;21(41):11502–11521. doi:10.3748/wjg.v21.i41.11502Ruiz-del-Á rbol L., Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol. 2015;21(41):11502–11521. doi:10.3748/wjg.v21.i41.11502Naqvi I. H., Mahmood K., Naeem M., Vashwani A. S., Ziaullah S. Th e heart matters when the liver shatters! Cirrhotic cardiomyopathy: frequency, comparison, and correlation with severity of disease. Prz Gastroenterol. 2016;11(4):247-256. doi:10.5114/pg.2016.57962Naqvi I. H., Mahmood K., Naeem M., Vashwani A. S., Ziaullah S. Th e heart matters when the liver shatters! Cirrhotic cardiomyopathy: frequency, comparison, and correlation with severity of disease. Prz Gastroenterol. 2016;11(4):247-256. doi:10.5114/pg.2016.57962Batchvarov V., Camm A. J., Gersh B. J., Downey B. C. QT dispersion: Measurement and interpretation. 2018. Available at: http://www.uptodate.com (Access on 2020 April 17)Batchvarov V., Camm A. J., Gersh B. J., Downey B. C. QT dispersion: Measurement and interpretation. 2018. Available at: http://www.uptodate.com (Access on 2020 April 17)Mozos I. Arrytmia risk in liver cirrhosis. World J Hepatol. 2015;7(4):662–672. doi:10.4254/wjh.v7.i4.662Mozos I. Arrytmia risk in liver cirrhosis. World J Hepatol. 2015;7(4):662–672. doi:10.4254/wjh.v7.i4.662Silvestre O., Farias A. Q., Ramos D., Furtado M. S., Rodrigues A., Ximenes R. O., et al. B-blocker therapy for cirrhotic cardiomyopathy: a ramdomised-controled trial. Eur J Gastroenterol Hepatol. 2018;30(8):930–937. doi:10.1097/MEG.0000000000001128Silvestre O., Farias A. Q., Ramos D., Furtado M. S., Rodrigues A., Ximenes R. O., et al. B-blocker therapy for cirrhotic cardiomyopathy: a ramdomised- controled trial. Eur J Gastroenterol Hepatol. 2018;30(8):930–937. doi:10.1097/MEG.0000000000001128Arslan U., Yenerçağ M. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World J Clin Cases. 2020 Oct 26;8(20):4688–4699. doi: 10.12998/wjcc.v8.i20.4688Arslan U., Yenerçağ M. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World J Clin Cases. 2020 Oct 26;8(20):4688–4699. doi: 10.12998/wjcc.v8.i20.4688Wong V.W-S., Wong G. L., Yeung J. C., Fung C. Y., Chan J. K., Chang Z. H., et al. Long-term clinical outcomes aft er fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology 2016;63(3):754–763. doi:10.1002/hep.28253Wong V.W-S., Wong G. L., Yeung J. C., Fung C. Y., Chan J. K., Chang Z. H., et al. Long-term clinical outcomes aft er fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology 2016;63(3):754–763. doi:10.1002/hep.28253Ma J., Hwang S. J., Pedley A., Massaro J. M., Hoff mann U., Chung R. T., et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66(2):390–397. doi:10.1016/j.jhep.2016.09.022Ma J., Hwang S. J., Pedley A., Massaro J. M., Hoff mann U., Chung R. T., et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66(2):390–397. doi:10.1016/j.jhep.2016.09.022Wu S., Wu F., Ding Y., Hou J., Bi J., Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep. 2016;6:33386. Published 2016 Sep 16. doi:10.1038/srep33386Wu S., Wu F., Ding Y., Hou J., Bi J., Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep. 2016;6:33386. Published 2016 Sep 16. doi:10.1038/srep33386Targher G., Byrne C. D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of in cident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589–600. doi:10.1016/j.jhep.2016.05.013Targher G., Byrne C. D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of in cident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589–600. doi:10.1016/j.jhep.2016.05.013Wild S. H., Walker J. J., Morling J. R., et al. Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes Care. 2018;41(2):341–347. doi:10.2337/dc17-1590Wild S. H., Walker J. J., Morling J. R., et al. Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes Care. 2018;41(2):341–347. doi:10.2337/dc17-1590Лазебник Л. Б., Голованова Е. В., Туркина С. В. И др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;185(1): 4–52. doi: 10.31146/1682–8658-ecg-185–1–4–52Lazebnik L. B., Golovanova E. V., Turkina S. V., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4– 52. (In Russ.) doi: 10.31146/1682–8658-ecg-185–1–4–52Трухан Д. И., Деговцов Е. Н., Давыдов Е. Л. Холецистокардиальный синдром в реальной клинической практике. Медицинский Совет. 2021;(4):212–219. doi:10.21518/2079–701X-2021–4–212–219Trukhan D. I., Degovtsov E. N., Davydov E. L. Cholec ystocardial syndrome in real clinical practice. Meditsinskiy sovet = Medical Council. 2021;(4):212–219. (In Russ.) doi:10.21518/2079–701X-2021–4–212–219Острый холецистит под маской острого инфаркта миокарда / А. Ю. Рябова, Т. Г. Шаповалова, М. М. Шашина [и др.] Экспериментальная и клиническая гастроэнтерология.2015; 2(114): 68–70.Ryabova A. Yu., Shapovalova T. G., Shashina M. M., et al. Acute cholecystitis disguised as acute myocardial infarction. Eksp Klin Gastroenterol. 2016;(2):68–70. (In Russ.)Оганезова И. А., Егорова С. В., Скворцова Т. Е., Медведева О. И. Холецистокардиальный синдром: трудности дифференциальной диагностики. Экспериментальная и клиническая гастроэнтерология. 2018;(2):110–114.Oganezova I.A., Egorova S. V., Skvortsova T. E., Med vedeva O. I. Сholecistocardiac syndrome: troubles of differential diagnosis. Experimental and Clinical Gastroenterology. 2018;(2):110–114. (In Russ.)Chevli P.A., Freedman B. I., Hsu F. C., et al. Plasma metabolomic profi ling in subclinical atherosclerosis: the Diabetes Heart Study. Cardiovasc Diabetol. 2021 Dec 7;20(1):231. doi: 10.1186/s12933–021–01419-yChevli P.A., Freedman B. I., Hsu F. C., et al. Plasma metabolomic profi ling in subclinical atherosclerosis: the Diabetes Heart Study. Cardiovasc Diabetol. 2021 Dec 7;20(1):231. doi: 10.1186/s12933–021–01419-yLi W., Shu S., Cheng L., Hao X., Wang L., Wu Y., Yuan Z., Zhou J. Fasting serum total bile acid level is associated with coronary artery disease, myocardial infarction and severity of coronary lesions. Atherosclerosis. 2020 Jan;292:193–200. doi: 10.1016/j.atherosclerosis.2019.11.026Li W., Shu S., Cheng L., Hao X., Wang L., Wu Y., Yuan Z., Zhou J. Fasting serum total bile acid level is associated with coronary artery disease, myocardial infarction and severity of coronary lesions. Atherosclerosis. 2020 Jan;292:193–200. doi: 10.1016/j.atherosclerosis.2019.11.026

The authors declare that there are no conflicts of interest present.